Expertise in
14
conditions

Dr. Laura W. Goff

Gastroenterology
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 
Accepting New Patients
Offers Telehealth
Expertise in
14
conditions
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 

Overview

Laura Goff is a Gastroenterologist practicing medicine in Nashville, Tennessee.

Dr. Goff is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Gallbladder Adenocarcinoma, Pancreaticoduodenectomy, and Liver Embolization.

She is actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 13 clinical trials. Dr. Goff is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in TN

Hospital Affiliations

Vanderbilt University Medical Center

Languages Spoken

English
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Biological, Drug
Study Drugs: Olaparib, Ramucirumab
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Enrollment Status: Terminated
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: CPI 613, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Enrollment Status: Terminated
Publish Date: October 21, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Cobimetinib, Varlilumab
Study Phase: Phase 2
A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Enrollment Status: Terminated
Publish Date: June 05, 2024
Intervention Type: Drug, Other
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
View 9 Less Clinical Trials

55 Total Publications

End-Of-Life Outcomes and Healthcare Utilization for Patients With Hepatocellular Carcinoma Who Received Immune Checkpoint Inhibition.
End-Of-Life Outcomes and Healthcare Utilization for Patients With Hepatocellular Carcinoma Who Received Immune Checkpoint Inhibition.
Journal: Cancer medicine
Published: May 08, 2025
Similar Doctors
Expertise in
14
conditions
Dr. Michael F. Vaezi
Gastroenterology
Expertise in
14
conditions
Dr. Michael F. Vaezi
Gastroenterology
Referral may be required

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-7427
Languages Spoken:
English, Farsi, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Vaezi is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Vaezi is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Esophagitis, Achalasia, Heartburn, and Endoscopy. Dr. Vaezi is currently accepting new patients.

Expertise in
11
conditions
Dr. David M. Schwartz
Gastroenterology
Expertise in
11
conditions
Dr. David M. Schwartz
Gastroenterology
Referral may be required

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-0128
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Schwartz is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Schwartz is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Pulmonary Fibrosis, Viral Gastroenteritis, Endoscopy, and Colonoscopy. Dr. Schwartz is currently accepting new patients.

Expertise in
18
conditions
Dr. Patrick S. Yachimski
Gastroenterology
Expertise in
18
conditions
Dr. Patrick S. Yachimski
Gastroenterology
Referral may be required

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-0128
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Yachimski is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Yachimski is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Barrett Esophagus, Pancreatic Pseudocyst, Neuroma Biliary Tract, Endoscopy, and Pancreatectomy. Dr. Yachimski is currently accepting new patients.

Frequently Asked Questions about Dr. Laura W. Goff

How do I make an appointment with Dr. Laura W. Goff?

You can book an appointment with Dr. Laura W. Goff by calling their office at 615-322-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Laura W. Goff a top-rated expert for Cholangiocarcinoma (Bile Duct Cancer)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Laura W. Goff is classified as an Distinguished expert for Cholangiocarcinoma (Bile Duct Cancer), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Laura W. Goff specialize in?

While Dr. Laura W. Goff is a Gastroenterology, they have specific expertise in Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, and Gallbladder Adenocarcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Laura W. Goff participate in research or clinical trials?

Yes. Dr. Laura W. Goff has published 55 articles and abstracts on conditions like Cholangiocarcinoma (Bile Duct Cancer). You can view a list of Dr. Laura W. Goff's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Laura W. Goff accept my insurance?

Dr. Laura W. Goff accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 615-322-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goff's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile